Evidence map›Paper›PMID 33956571›Full record

ReviewSmall GTPases2022

A signalling cascade for Ral.

You Wu, David J Reiner

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Small GTPases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

You Wu
David J ReinerTexas A&M University, Houston, TX, USA.
Texas A&M University · US

Funding

Understanding Ras effector switching and roles of Ras>RalGEF>Ral in developmentR35GM144237 · NIGMS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI David Reiner · 2022 to 2026
$1.9M
Novel signals regulate cell fate patterning - Equipment SupplementR01GM121625 · NIGMS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI REINER, DAVID · 2017 to 2020
$1.4M
NIGMS NIH HHS R01 GM121625NIGMS NIH HHS R35 GM144237
6 · The paper itself

Abstract

Ras is the most mutated oncoprotein in cancer. Among the three oncogenic effectors of Ras - Raf, PI3 Kinase and RalGEF>Ral - signalling through RalGEF>Ral (Ras-like) is by far the least well understood. A variety of signals and binding partners have been defined for Ral, yet we know little of how Ral functions

Indexed as

Caenorhabditis elegansSignal TransductionAnimalsDrosophilaPhosphatidylinositol 3-KinasesPhosphatidylinositol 3-KinasesExo84Exoc-8ExocysthppyLET-60MLK-1msnPMK-1Ral-1Rgl-1Sec-5Sec5

Identifiers

PMID33956571
PMCPMC9707527
OpenAlexW3158846237

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.